Condition: Rejection Acute Hepatic · Transplant; Failure, Liver · Liver Dysfunction · Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
A lot of different early and late complications may occur after liver transplantation. They could be related to surgical procedure, to infectious diseases or immuno-mediated diseases (acute cellular rejection, ACR). Almost all of those complications are characterized by an elevation in liver enzymes (ALT, AST and GGT) and a decline of liver function tests (serum bilirubin and INR increase) possibly leading to early allograft disfunction (EAD). In this scenario there is a lack of biomarker that could predict the development of ACR and/or EAD. The aim of this study is to explore the prognostic role of non-invasive instrumental and biological marker in the early post-transplant phase.
This description comes directly from the study's public registry record.
Luca Miele, MD, PhD · +390630151 · luca.miele@policlinicogemelli.it
Always discuss trial participation with your own doctor first.
| Fondazione Policlinico Universitario A. Gemelli IRCCS | Rome, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05793203